Compare ODC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | KALV |
|---|---|---|
| Founded | 1941 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1994 | 2014 |
| Metric | ODC | KALV |
|---|---|---|
| Price | $78.07 | $26.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 33.0K | ★ 4.4M |
| Earning Date | 06-04-2026 | 07-09-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | N/A | $59.23 |
| P/E Ratio | $46.10 | ★ N/A |
| Revenue Growth | 10.97 | ★ 495.66 |
| 52 Week Low | $45.61 | $9.83 |
| 52 Week High | $78.25 | $26.85 |
| Indicator | ODC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 68.58 | 75.12 |
| Support Level | $70.67 | $14.66 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.07 | 0.25 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 84.43 | 98.93 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.